A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer

  • End date
    Sep 30, 2024
  • participants needed
  • sponsor
    Asan Medical Center
Updated on 26 January 2021


This study aims to assess objective response rate of modified FOLFIRINOX in advanced urachaus cancer.

Patients with locally advanced, recurrent, or metastatic urachal carcinoma of bladder, urachal will be enrolled this study.

Modified version of FOLFIRINOX(Oxaliplatin 85 mg/m 2, Leucovorin 400mg/m2 , irinotecan 150mg/m2 and 5-FU 2400mg/m2) with prophylactic pegateograstim will be continued till progression, unacceptable toxicity, or till 12 cycles (24 weeks). Study drugs can be administered after 12 cycles to the subjects with benefit from study medication.

Response evaluation will be done every 6 weeks.

Condition Urachal Cancer
Clinical Study IdentifierNCT04611724
SponsorAsan Medical Center
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed adenocarcinoma of bladder/urachal remnant that is clinically consistent with urachal cancer
Origin in the anterior wall or dome of the bladder Predominant invasion of
muscularis or deeper tissues No obvious origin from the overlying urothelium
(relative normal-looking urothelial mucosa) No primary adenocarcinoma
Patients with locally advanced, recurrent, or metastatic disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent
No prior systemic therapy for advanced urachal cancer. For recurrent disease, previous 5-FU, oxaliplatin, or irinotecan chemotherapy as neoadjuvant and/or adjuvant aim is allowed if it ended more than 6 months before enrollment
Measurable disease according to RECIST v1.1 criteria
ECOG performance status 0 or 1
Age 19 years or older
Adequate cardiac function
Adequate bone marrow, hepatic, and renal function Hematology
Life expectancy more than 3 months
Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Exclusion Criteria

Age > 65
Previous radiotherapy to the only measurable lesion: but previous radiotherapy will be permitted unless the lesion is the only measurable lesion
Uncontrolled CNS metastasis (brain and/or leptomeningeal metastasis)
Grade 2 or more peripheral neuropathy
Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri or prostate cancer and curatively treated thyroid cancer of any stage
Pregnancy or breast feeding, or intention of becoming pregnant during study treatment or within 6 months after final dose
Other severe acute or chronic medical or psychiatric condition
Chronic diarrhea
Clinically significant cardiac disease (heart failure, coronary artery disease, and/or arrhythmia)
Hypersensitivity to study medication
treatment with a prohibited medication or anticipation of need for prohibited medication ( section 5.5 )
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note